Regeneron Pharmaceuticals Inc (REGN)

Pretax margin

Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020
Earnings before tax but after interest (EBT) (ttm) US$ in thousands 5,145,100 4,874,800 4,984,200 4,779,900 4,969,400 4,587,200 4,042,000 4,199,300 4,376,400 4,775,400 4,655,700 4,858,800 6,037,500 6,344,300 9,133,900 9,325,800 8,047,000 7,228,700 4,394,800 3,810,400
Revenue (ttm) US$ in thousands 14,247,800 14,214,200 14,085,700 14,202,000 13,847,100 13,489,100 13,100,100 13,117,200 13,097,300 12,670,800 12,369,900 12,172,900 13,710,200 14,226,800 16,508,100 16,071,700 13,542,900 12,384,100 9,197,600 8,497,100
Pretax margin 36.11% 34.30% 35.38% 33.66% 35.89% 34.01% 30.85% 32.01% 33.41% 37.69% 37.64% 39.91% 44.04% 44.59% 55.33% 58.03% 59.42% 58.37% 47.78% 44.84%

September 30, 2025 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $5,145,100K ÷ $14,247,800K
= 36.11%


Peer comparison

Sep 30, 2025

Company name
Symbol
Pretax margin
Regeneron Pharmaceuticals Inc
REGN
36.11%
Arrowhead Pharmaceuticals Inc
ARWR
6.62%
Biomarin Pharmaceutical Inc
BMRN
21.95%